Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FOREST SYNCHRON PRODUCTS UNDER AGREEMENTS WITH SYNTEX AND UPJOHN

Executive Summary

FOREST SYNCHRON PRODUCTS UNDER AGREEMENTS WITH SYNTEX AND UPJOHN remain included in claims for the technology allowed by the U.S. Patent Office, Forest noted in an Aug. 12 press release. Commenting on a ruling by the Patent Office that rejected Dow's administrative challenge to the Synchron patent, Forest President Howard Solomon said: "The patent claims now confirmed by the Patent Office, although modified in minor respects from the claims originally allowed, cover all the essentials of that technology. All products we have ever developed in which we have utilized this technology, including the products covered by agreements with Upjohn and Syntex, are included within the allowed claims." Responding to Forest's announcement, Dow issued the following statement: "Dow believes the new patent claims to be invalid in view of prior art in spite of the recent Patent Office action. Dow intends to contest the new patent claims and is reviewing available options. A decision should be made within 90 days." The Michigan-based chemical mfr. also noted that in the interim it was advising potential customers on alternate formulation methods "that avoid the new narrow claims of the patent." Dow's initial request to re-examine the Forest Synchron patent was filed in the fall of 1983 and subsequently denied by the Patent Office in January 1984. Subsequently, the company asked the Patent Office to re-examine the patent. The agency agreed to the re-examination in May 1984 ("The Pink Sheet" June 11, 1984, T&G-7). * The patent in question, U.S. 4,389,393, is one of five patents held by Forest for the sustained release technology and covers two forms of hydroxpropyl methylcellulose (Methocel) as the binder.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel